Long-term follow-up for people with BAP1 mutations
Part of Cancer clinical trials.
This study follows people with a harmful (deleterious) BAP1 gene change to learn how it affects health over time. It may help researchers better understand mesothelioma risk and the long-term outcomes for families with this genetic mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 2 or older
- You (or a tested relative, in some cases) have a germline BAP1 gene mutation
- If you have mesothelioma yourself, your BAP1 result can be from research or clinical testing
- If you do not have mesothelioma, you generally need a lab-confirmed BAP1 result done under certified testing (like CLIA)
- You must agree to sign a written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
This study tests an oral medication called decitabine/cedazuridine (INQOVI) that may help delay or prevent progression in people with early-stage mesothelioma who carry a BAP1 mutation. The treatment is given as a pill and aims to reactivate genes that may help control cancer growth.
This study collects tissue samples (biopsies) and health information to better understand malignant mesothelioma and certain related solid tumors that may produce a protein called mesothelin. It may help future research and treatments, and you can only join if your diagnosis is confirmed and it’s safe for you to have the tissue taken.
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.